World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
77
Citations
18866
World Ranking
18531
National Ranking
73

Jae Weon Kim publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jae Weon Kim sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 449 publications — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Jae Weon Kim D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jae Weon Kim sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 77 D-Index — 10th percentile

10% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Jae Weon Kim is affiliated with Seoul National University in South Korea and has a research focus primarily within the field of Medicine. Their work spans multiple subfields, including Reproductive Medicine, Obstetrics and Gynecology, Oncology, Surgery, and Epidemiology.

Their research concentrates on specific topics such as ovarian cancer diagnosis and treatment, endometrial and cervical cancer treatments, PARP inhibition in cancer therapy, cervical cancer and HPV research, intraperitoneal and appendiceal malignancies, BRCA gene mutations in cancer, and endometriosis research and treatment.

Frequent coauthors contributing significantly alongside Jae Weon Kim include Se Ik Kim, Hee Seung Kim, Maria Lee, Chel Hun Choi, and Hyun Hoon Chung.

Jae Weon Kim has published considerable work across key academic venues, with frequent publications found in:

  • Gynecologic Oncology
  • Journal of Gynecologic Oncology
  • International Journal of Gynecological Cancer
  • Journal of Clinical Oncology
  • E-Posters

Notable recent papers authored or co-authored by Jae Weon Kim include:

  • Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer, 2024, New England Journal of Medicine
  • Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial, 2020, Journal of Clinical Oncology
  • Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20., 2020, Journal of Clinical Oncology
  • Is coronavirus disease (COVID-19) seasonal? A critical analysis of empirical and epidemiological studies at global and local scales, 2021, Environmental Research
  • Endometrial carcinosarcoma, 2022, International Journal of Gynecological Cancer

Best Publications

  • Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

    Eric Pujade-Lauraine;Jonathan A Ledermann;Frédéric Selle;Val Gebski

  • Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer

    Andreas Du Bois;Anne Floquet;Jae Weon Kim;Jae Weon Kim;Joern Rau

  • Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer

    Marcus E. Randall;Virginia Filiaci;D. Scott McMeekin;Vivian Von Gruenigen

  • Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer

    Robert L. Coleman;Nick M. Spirtos;Danielle Enserro;Thomas J. Herzog

  • Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial.

    Richard T. Penson;Ricardo Villalobos Valencia;David Cibula;Nicoletta Colombo

  • Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002).

    Jeong-Yeol Park;Dae-Yeon Kim;Jong-Hyeok Kim;Yong-Man Kim

  • Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20.

    A DuBois;I Vergote;G Ferron;A Reuss

  • Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

    Andrew R. Clamp;Elizabeth C. James;Iain A. McNeish;Andrew Dean

  • Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: an international collaborative meta-analysis.

    H.S. Kim;J.E. Sardi;N. Katsumata;H.S. Ryu

  • TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies

    Stefanie J. Klug;Meike Ressing;Jochem Koenig;Martin C. Abba

  • Comparison of survival outcomes between minimally invasive surgery and conventional open surgery for radical hysterectomy as primary treatment in patients with stage IB1-IIA2 cervical cancer.

    Se Ik Kim;Jae Hyun Cho;Aeran Seol;Young Im Kim

  • Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence.

    Hyun Hoon Chung;Hoenil Jo;Won Jun Kang;Jae Weon Kim

  • Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian germ cell tumors.

    Jubilee Brown;Michael Friedlander;Floor J. Backes;Philipp Harter

  • Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma.

    Dominique Berton-Rigaud;Mojgan Devouassoux-Shisheboran;Jonathan A. Ledermann;Mario M. Leitao

  • Prognostic Value of Preoperative Metabolic Tumor Volume and Total Lesion Glycolysis in Patients with Epithelial Ovarian Cancer

    Hyun Hoon Chung;Hyun Woo Kwon;Keon Wook Kang;Noh-Hyun Park

  • Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer.

    Hyun Hoon Chung;Jae Weon Kim;Kyung Hee Han;Jae Seon Eo

  • Preoperative Identification of a Low-Risk Group for Lymph Node Metastasis in Endometrial Cancer: A Korean Gynecologic Oncology Group Study

    Sokbom Kang;Woo Dae Kang;Hyun Hoon Chung;Dae Hoon Jeong

  • Current status of gynecological cancer in China

    Kidong Kim;Rongyu Zang;Seok Cheol Choi;Sang Young Ryu

  • Trophoblastic disease review for diagnosis and management: a joint report from the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup.

    Giorgia Mangili;Domenica Lorusso;Jubilee Brown;Jacobus Pfisterer

  • Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings.

    Hyun Hoon Chung;Won Jun Kang;Jae Weon Kim;Noh-Hyun Park

Frequent Co-Authors

Yong Sang Song
Yong Sang Song Seoul National University
Michael Friedlander
Michael Friedlander University of New South Wales
Nicoletta Colombo
Nicoletta Colombo University of Milano-Bicocca
Young Tae Kim
Young Tae Kim Seoul National University Hospital
Jonathan A. Ledermann
Jonathan A. Ledermann University College London
Daehee Kang
Daehee Kang Seoul National University
Keun-Young Yoo
Keun-Young Yoo Seoul National University
Giovanni Scambia
Giovanni Scambia Catholic University of the Sacred Heart
Sandro Pignata
Sandro Pignata National Cancer Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online education can open the door to many healthcare careers beyond the traditional MD route. If you're interested in the business side of medicine, medical billing and coding schools online with financial aid offer flexible, affordable training for in-demand administrative roles.

For those drawn to patient care but seeking a faster or alternative entry point, consider becoming a Licensed Practical Nurse (LPN). There are excellent lpn school without teas test programs, letting you skip common entrance exams and get started sooner.

If you already work in healthcare and want to advance, pursue an accelerated healthcare administration degree online. These programs help you quickly move into leadership and management positions.

Nurses with an associate degree can also progress to advanced clinical roles through specialized asn to fnp programs, bridging the gap from RN to Family Nurse Practitioner.

Each of these paths offers unique opportunities for career growth and lets you make a difference in healthcare—without taking the traditional medical school route.

Best Scientists Citing Jae Weon Kim

Trending Scientists

Recently Published Articles